Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribocicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzaniga, Marina Elena, Ciaccio, Antonio, Danesi, Romano, Duhoux, Francois P., Girmenia, Corrado, Zaman, Kalhil, Lindman, Henrik, Luppi, Fabrizio, Mavroudis, Dimitrios, Paris, Ida, Olubukola, Ayodele, Samreen, Ahmed, Schem, Christian, Singer, Christian, Snegovoy, Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639170/
https://www.ncbi.nlm.nih.gov/pubmed/37954071
http://dx.doi.org/10.3389/fonc.2023.1247270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639170/
https://www.ncbi.nlm.nih.gov/pubmed/37954071
http://dx.doi.org/10.3389/fonc.2023.1247270

Ejemplares similares